Future outlook: what comes next for both compounds The peptide weight loss landscape is evolving rapidly, and both cagrilintide and retatrutide sit at the center of that evolution
According to some of those legal complaints, patients had to be hospitalized or seek urgent medical attention because of these side effects
One article found an increased incidence of aspiration pneumonia among GLP-1 users compared to non-users reporting a hazard ratio of 1.33 (95%CI 1.021.74, p = 0.036) (Australian Diabetes Society, National Association of Clinical Obesity Services, Gastroenterological Society of Australia, and Australian and New Zealand College of Anaesthetists n.d.)
This approach supports the natural system rather than suppressing it.
This is harder on GLP-1s because your appetite is suppressedyou need to prioritize protein even when you don't feel like eating
Journal of Clinical Endocrinology & Metabolism, 62(3), 536-541